Entheon Biomedical Announces EBIQ-101 First-Patient Dose
Entheon Biomedical Announces EBIQ-101 First-Patient Dose
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its Observational Study, EBIQ-101.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年2月24日)-Entheon Biomedical Corp.(CSE：ENBI)(OTCQB：ENTBF)(FSE：1XU1)(“恩瑟恩“或”公司“)，一家專注於迷幻藥物和尖端生物標記物的研究和開發，為成癮障礙提供個性化治療的生物醫藥公司，很高興提供其觀察性研究的最新情況，EBIQ-101。
We are pleased to report that the first patient has been dosed in EBIQ-101, a study using electroencephalography (EEG) to observe variability in neurological activity in patients prior to, during, and after ketamine treatments. The study will also assess genetic markers prior to ketamine treatment to evaluate the correlation of neurological phenotypes with genetic markers. More details on the study can be found at ClinicalTrials.gov.
我們很高興地報告，第一位患者已經服用了EBIQ-101，這是一項使用腦電圖(EEG)觀察患者在氯胺酮治療之前、期間和之後神經活動的變異性的研究。該研究還將在氯胺酮治療前評估遺傳標記，以評估神經表型與遺傳標記的相關性。有關這項研究的更多細節，請訪問ClinicalTrials.gov。
The results of EBIQ-101 will serve as the foundation for the strategic aims of Entheon IQ™ and Entheon ID™, the development of a framework for characterizing the psychedelic drug state of patients, and to research phenotypes associated with particular addictions and mental health disorders.
EBIQ-101的結果將作為Entheon IQ™和Entheon ID™戰略目標的基礎，開發一個框架來描述患者的迷幻藥物狀態，並研究與特定成癮和精神健康障礙相關的表型。
About Entheon Biomedical Corp.
Entheon Biomedical Corp.簡介
Entheon is a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders. Entheon is comprised of three divisions, Entheon RX™, focused on the development of therapeutic drugs, using N, N-dimethyltryptamine (DMT) as the pharmacological benchmark; Entheon ID™, focused on identification, analysis and predictive use of EEG biomarkers and genetics in the selection and management of drug treatment; and Entheon IQ™, focused on the development of treatment algorithms through the analysis of patient data. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
Entheon是一家生物醫藥公司，專注於迷幻藥物和前沿生物標記物的研究和開發，為成癮障礙提供個性化治療。Entheon由三個部門組成，Entheon RX™，專注於治療藥物的開發，使用N，N-二甲基色胺(T.N：行情)DMT作為藥理學基準的Entheon ID™；Entheon ID™，側重於腦電生物標誌物和遺傳學在藥物治療選擇和管理中的識別、分析和預測性使用；以及Entheon IQ™，側重於通過分析患者數據開發治療算法。在獲得所有必要的監管批准和許可後，Entheon公司打算通過向美國、歐盟某些國家和加拿大各地的醫生、診所和有執照的精神病學家銷售其DMT產品來創造收入。
For more information, please contact the Company at:
如需更多信息，請聯繫本公司，網址為：
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
Entheon Biomedical Corp.
約瑟夫·庫倫(Joseph Cullen)，投資者關係部
電話：+1(778)919-8615
郵箱：Joe@entheonbibiedical.com
For media inquiries, please contact Elizabeth Glassen of BlueSky Communications at:
如有媒體查詢，請聯繫藍天通信公司的伊麗莎白·格拉森(Elizabeth Glassen)，電話：
BlueSky Communications
Elizabeth Glassen, Account Manager
Telephone: +1 (647) 309-0141
eglassen@blueskycommunications.com
藍天通信
客户經理Elizabeth Glassen
電話：+1(647)309-0141
郵箱：eglassen@BlueskyCommunications.com
Cautionary Note on Forward-Looking Information
關於前瞻性信息的警示説明
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the timeline relating to the launch of EBIQ-101, the Company's planned clinical trial, results of trials and studies, and the expected outcome and timeline for results and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, but not limited to, assumptions relating to the continued impact and status of COVID-19 on the Company's personnel and planned research activities, that general economic and political conditions will remain the same, stability in applicable law and regulations. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
本新聞稿包含符合適用證券法的前瞻性陳述和前瞻性信息。這些陳述與未來事件或未來表現有關。除歷史事實以外的所有陳述都可能是前瞻性陳述或信息。更具體地説，本新聞稿包含前瞻性陳述和信息，涉及與EBIQ-101的推出有關的時間表、該公司計劃的臨牀試驗、試驗和研究結果，以及結果和其他事項的預期結果和時間表。前瞻性陳述和信息基於公司管理層做出的某些重要預期和假設，包括但不限於與新冠肺炎對公司人員和計劃中的研究活動的持續影響和地位有關的假設，總體經濟和政治條件將保持不變，以及可適用法律法規保持穩定的假設。儘管公司管理層認為這些前瞻性陳述和信息所基於的預期和假設是合理的，但不應過度依賴前瞻性陳述和信息，因為不能保證它們將被證明是正確的。
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, a rise in the number of COVID cases globally, an adverse impact of COVID on the research activities of the Company and its research partners, the inability to prepare the IMPD submission within the time frame expected, difficulties in subject enrollment, initial screening or site initiation, delays to the Company's planned clinical trial timeline as a result of other unknown uncertainties and adverse changes to applicable law and regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
提供前瞻性陳述和信息的目的是提供有關公司目前對未來的期望和管理計劃的信息。提醒讀者，依賴此類報表和信息可能不適合用於其他目的，如做出投資決策。由於前瞻性陳述和信息涉及未來事件和情況，它們本身就包含固有的風險和不確定因素。由於一些因素和風險，實際結果可能與目前預期的大不相同。這些因素包括但不限於全球COVID病例數量的增加、COVID對公司及其研究夥伴的研究活動的不利影響、無法在預期的時間框架內準備提交的IMPD、受試者登記、初始篩選或臨牀試驗啟動方面的困難、由於其他未知不確定性以及適用法律和法規的不利變化導致公司計劃的臨牀試驗時間表的延誤。因此，讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。提醒讀者，前面列出的因素並不是詳盡的。本新聞稿中包含的前瞻性陳述和信息是截至本新聞稿發佈之日的前瞻性陳述和信息，除非適用的證券法要求，否則不承諾公開更新或修改任何前瞻性陳述或信息，無論是由於新信息、未來事件還是其他原因。本新聞稿中包含的前瞻性陳述或信息明確受本警告性聲明的限制。
Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
CSE和加拿大投資行業監管組織均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。